Infection and Drug Resistance (Apr 2024)

Nab-Paclitaxel for Relapsed AIDS-Related Kaposi Sarcoma -A Case Report

  • Yu L,
  • Zhang B,
  • Wan H

Journal volume & issue
Vol. Volume 17
pp. 1431 – 1437

Abstract

Read online

Lele Yu, Binhai Zhang, Hu Wan Department II of Infectious Diseases, Hangzhou Xixi Hospital, Hangzhou Sixth People’s Hospital, Hangzhou, Zhejiang, 310023, People’s Republic of ChinaCorrespondence: Hu Wan, Email [email protected]: Kaposi sarcoma (KS) incidence has decreased since the initiation of combination antiretroviral therapy (cART), but it remains the most common cancer in people with HIV/AIDS (PWHA). PWHA with advanced immunosuppression who initiate antiretroviral therapy are susceptible to the occurrence of an immune reconstitution inflammatory syndrome (IRIS).Case Presentation: This report covers the case of a 25-year-old male with AIDS-related KS who relapsed after Liposomal Doxorubicin, but recovered well after administration of nab-paclitaxel (Nab-PTX).Conclusion: This is a rare case in choosing Nab-PTX to treat relapsed AIDS-KS and get good feedback. We report the case to provide a possible solution to treat AIDS-KS.Keywords: Kaposi sarcoma, nab-paclitaxel, HIV, case report

Keywords